PharmTech LCGC Sciex Webinar 11.10
|Articles|September 1, 2008

Seegene and Shimadzu Form Partnership for Pathogen Detection

Seegene, Inc. (Rockville, Maryland) and Shimadzu Corporation (Columbia, Maryland) announced that they had formed a strategic partnership to combine Seegene's Seeplex multipathogen tests with Shimadzu's MultiNA high-speed electrophoresis system.

Seegene, Inc. (Rockville, Maryland) and Shimadzu Corporation (Columbia, Maryland) announced that they had formed a strategic partnership to combine Seegene's Seeplex multipathogen tests with Shimadzu's MultiNA high-speed electrophoresis system. The companies will collaborate on integrating the polymerase chain reaction-based tests with the electrophoresis system to provide a highly sensitive, high-throughput detection and analysis system. The microchip electrophoresis system is designed for DNA and RNA nucleic acid size confirmation and quantification, and the tests reportedly are capable of detecting multiple pathogens in a single tube, including STDs, respiratory viruses, human papillomaviruses, sepsis, and pneumonia.


Related to this article

Best of the Week: From Cancer Diagnostics to Smarter LC Method Development
This week, Chromatography Online’s coverage spanned lipidomics-based early cancer detection, career paths in separation science, machine learning and uncertainty-driven approaches to LC method development, new EU wastewater rules for pharmaceutical micropollutants, automated Separation Quality Factor (SQF) evaluation in chromatography data systems, and solutions to GLP-1 peptide analysis challenges.